ShangPharma (SHP) Receives First Milestone in Research Partnership with Hengrui
Tweet
Share
E-mailGet Alerts SHP Hot Sheet
Join SI Premium – FREE
ShangPharma Corporation (NYSE: SHP) today announced that it has reached the first milestone in its strategic partnership with Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, to develop novel therapeutic monoclonal antibodies.
The long-term collaborative project includes three additional specific milestone targets. The goal of the strategic partnership is to deliver a drug candidate.
"Achieving this first milestone is an important step forward in our development of therapeutic antibodies," said Dr. Lianshan Zhang, Hengrui's President of Global R&D. "We are pleased that we have achieved this just a few months into our strategic partnership with ShangPharma's biologics division."
"We are delighted that this ground breaking collaboration to develop novel therapeutic monoclonal antibodies in China is rapidly producing results," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "We believe that reaching this strategically important milestone is just the first of many achievements that the relationship between ShangPharma and Hengrui will yield."
The long-term collaborative project includes three additional specific milestone targets. The goal of the strategic partnership is to deliver a drug candidate.
"Achieving this first milestone is an important step forward in our development of therapeutic antibodies," said Dr. Lianshan Zhang, Hengrui's President of Global R&D. "We are pleased that we have achieved this just a few months into our strategic partnership with ShangPharma's biologics division."
"We are delighted that this ground breaking collaboration to develop novel therapeutic monoclonal antibodies in China is rapidly producing results," said Michael Xin Hui, founder and Chief Executive Officer of ShangPharma. "We believe that reaching this strategically important milestone is just the first of many achievements that the relationship between ShangPharma and Hengrui will yield."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Real and RE/MAX Holdings receive court approval for merger
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
